TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11421998
Drug: Sulpiride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (10 mg kg‐1)
Study: 25549517
Drug: Intrusive force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrusive force of 100 g delivered from mini-implants for 6 months
Study: 20837952
Drug: Regimen 1A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1A: Irinotecan 20 mg/m(2)/d intravenously for 5 days at weeks 1, 2, 4, and 5 with vincristine 1.5 mg/m(2) on day 1 of weeks 1, 2, 4, and 5
Study: 20837952
Drug: Regimen 1B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1B: Irinotecan 50 mg/m(2)/d intravenously for 5 days at weeks 1 and 4 with vincristine as in regimen 1A
Study: 18443034
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 500 mg
Study: 15983224
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg intravenously from ‐30 to ‐15 min) with GLP-1
Study: 1440118
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.12% chlorhexidine gluconate (Peridex, Procter & Gamble)
Study: 1440118
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL placebo
Study: 31403610
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g·d for 7 days)
Study: 26888096
Drug: Para (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Para (1000 mg paracetamol)
Study: 26888096
Drug: Para‐Caf (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Para‐Caf (1000 mg paracetamol/130 mg caffeine)
Study: 23856296
Drug: AZD3480 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 50 mg
Study: 15752944
Drug: ACEi (Angiotensin-Converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi (Angiotensin-Converting Enzyme Inhibitor)
Study: 15752944
Drug: ARB (Angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (Angiotensin II Receptor Blocker)
Study: 29445269
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin oral controlled absorption system (OCAS)
Study: 29445269
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin OCAS
Study: 23470848
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza vaccines (TIV)
Study: 21707573
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate shampoo 0.05% (CP) twice weekly alternating with ketoconazole shampoo 2% (KC) twice weekly
Study: 21707573
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate shampoo 0.05% (CP) twice weekly (C2)
Study: 21707573
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate shampoo 0.05% (CP) four times weekly alternating with ketoconazole shampoo 2% (KC) twice weekly (C4+K2)
Study: 21707573
Drug: Ketoconazole shampoo
Normalized name: ketoconazole Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole shampoo 2% (KC) twice weekly (K2)
Study: 27010377
Drug: r‐TMS at
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐TMS at frequencies of 5 Hz and 10 Hz for 15 minutes daily for 20 days combined with standard therapy (ST) of 1 hour daily.
Study: 27010377
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ST) of 1 hour daily for 20 days.
Study: 22464340
Drug: Biological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatment (additional infliximab)
Study: 22464340
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (additional sulfasalazine and hydroxychloroquine)
Study: 14736626
Drug: Face-to-face delivered
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face delivered treatment
Study: 14736626
Drug: Booklet delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booklet delivered treatment
Study: 1343377
Drug: Silymarin (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (280 mg/day)
Study: 3905343
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml anhydrous theophylline dissolved in 20% pure alcohol, loading dose of 5 mg/kg and then 1.25 mg/kg every 6 h
Study: 31370751
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine (group L, n = 40)
Study: 22684154
Drug: Minimally-invasive surfactant
Normalized name: surfactant protein-D homotrimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally-invasive surfactant therapy (MIST)
Study: 21675494
Drug: Doxepin cream
Normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin cream 5%
Study: 18988089
Drug: Betamethasone cream
Normalized name: Betamethasone Cream
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone cream 0.1%
Study: 19704057
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 30 mg intramuscularly in monthly intervals
Study: 12630026
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hepatitis B virus vaccination (40 mcg) with a shortened immunization schedule
Study: 7694528
Drug: Desflurane anesthesia
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane anesthesia with epinephrine doses of 7.0-13.0 micrograms/kg
Study: 7694528
Drug: Isoflurane anesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane anesthesia with epinephrine doses of 7.0-13.0 micrograms/kg
Study: 7694528
Drug: Both anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both anesthetic groups with epinephrine doses less than 7.0 micrograms/kg
Study: 4053529
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac (100 mg tablets of slow-release diclofenac)
Study: 11135723
Drug: Sustained-release hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release hydromorphone (8, 16, and 32 mg)
Study: 11135723
Drug: Immediate-release hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release hydromorphone (8 mg)
Study: 7857346
Drug: pidotimod 50
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pidotimod 50 mg, 100 mg, 200 mg twice a day
Study: 7857346
Drug: pidotimod (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: pidotimod (any dosage)
Study: 7857346
Drug: pidotimod 400
Normalized name: pidotimod 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pidotimod 400 mg/day
Study: 2706957
Drug: 10 widely
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 widely used surfactants and 1 solubilizer applied in aqueous solutions of 12.5 millimoles/l for 45 min twice daily for 3 weeks
Study: 21304253
Drug: Morning medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning medication (50 mg of naftopidil once a day after breakfast for 8 weeks)
Study: 21304253
Drug: Evening medication
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening medication (50 mg of naftopidil once a day after supper for 8 weeks)
Study: 21304253
Drug: Morning medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning medication (50 mg of naftopidil)
Study: 21304253
Drug: Evening medication
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening medication (50 mg of naftopidil)
Study: 19736473
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA), 5 mg/day
Study: 19736473
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA), 5 mg/day + vitamin B12, 1 mg/day
Study: 19736473
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA), 15 mg/day
Study: 19736473
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA), 15 mg/day + vitamin B12, 1 mg/day
Study: 11106014
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel only (Control)
Study: 3335295
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate, amoxicillin, and the combination of colloidal bismuth subcitrate and amoxicillin
Study: 3335295
Drug: Amoxicillin monotherapy
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin monotherapy
Study: 28302406
Drug: Microalgae oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microalgae oil (2.1 g DHA/d)
Study: 21369788
Drug: Increased sunlight
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased sunlight exposure (additional 30‐40 min/day in the early morning) with calcium supplementation (600 mg/day)
Study: 19576114
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage targeting goal (SDTG) group - atorvastatin 10 mg/d
Study: 19576114
Drug: Intensive dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive dosage targeting goal (IDTG) group - atorvastatin 20-80 mg/d
Study: 19576114
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage non-targeting goal (SDNTG) group - atorvastatin 10 mg/d without targeting goal
Study: 19576114
Drug: All dosages
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosages of atorvastatin (10 mg, 20 mg, 40 mg, 80 mg)
Study: 17767636
Drug: Propofol-ketamine (PK)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-ketamine (PK) - 1 mg x kg(‐1) ketamine + 1.2 mg x kg(‐1) propofol
Study: 17767636
Drug: Propofol-fentanyl (PF)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-fentanyl (PF) - 1 microg x kg(‐1) fentanyl + 1.2 mg x kg(‐1) propofol
Study: 14687871
Drug: Olanzapine (5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-25 mg/day)
Study: 14687871
Drug: Clozapine (100-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (100-500 mg/day)
Study: 12405466
Drug: Pilocarpine dissolved
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine dissolved in artificial saliva administered in a mouth spray
Study: 7821274
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g VGB
Study: 7821274
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g VGB
Study: 7821274
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g VGB
Study: 96473
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg i.v. pretreatment
Study: 30765242
Drug: MMRV (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV (two doses of combined measles-mumps-rubella-varicella vaccine)
Study: 30765242
Drug: MMR +
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR + V (one dose of live attenuated varicella vaccine after one dose of measles-mumps-rubella vaccine)
Study: 30765242
Drug: MMR (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR (two doses of measles-mumps-rubella vaccine)
Study: 28676211
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to pemetrexed/cisplatin (PC) chemotherapy
Study: 28676211
Drug: Pemetrexed/cisplatin (PC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed/cisplatin (PC) chemotherapy alone
Study: 24200199
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of Bifilact(®) probiotics (1.3 billion CFU, twice a day)
Study: 24200199
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of Bifilact(®) probiotics (1.3 billion CFU, twice a day) in patients who had surgery
Study: 22596211
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 200 mg + Methotrexate (MTX)
Study: 19058924
Drug: Non-active control
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active control condition (e.g., placebo or attention-only control)
Study: 19058924
Drug: Validated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validated treatment via a different modality
Study: 19058924
Drug: Tests of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tests of the new treatment as an add-on to standard treatment
Study: 19058924
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of dose-response design
Study: 19058924
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of optimal therapy to those who fail during the study
Study: 19058924
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of the experimental treatment vs. standard treatment
Study: 17160407
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 microg twice daily for 4 weeks, then 10 microg thereafter)
Study: 456272
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.25 mg g-strophanthin
Study: 456272
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 6.0 mg g-strophanthin
Study: 30674348
Drug: Online self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-help program ('Restart') based on cognitive behavioral therapy (CBT)
Study: 23392147
Drug: Sugared chewing
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugared chewing gum (Gum) - instructed to chew 3 times daily for 45 minutes each time for 7 days postoperatively
Study: 21248332
Drug: TS-11-MG vaccine
Normalized name: L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Prefilled Syringe [Gardasil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-11-MG vaccine
Study: 21248332
Drug: Bacterin +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bacterin + TS-11-MG combined
Study: 19283449
Drug: Adjusted body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted body weight (ABW) dosing of enoxaparin
Study: 19283449
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of enoxaparin
Study: 16211988
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg orally 3 hours before and 3 hours after the procedure
Study: 9856543
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (10 mg x kg(‐1))
Study: 8929239
Drug: GE uncrushed
Normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GE uncrushed (120 mg myrtol standardized)
Study: 8929239
Drug: GE crushed
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GE crushed (120 mg myrtol standardized)
Study: 8929239
Drug: GF uncrushed
Normalized name: Codar GF
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GF uncrushed (300 mg myrtol standardized)
Study: 8929239
Drug: GF crushed
Normalized name: Codar GF
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GF crushed (300 mg myrtol standardized)
Study: 2191783
Drug: Warfarin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin administered simultaneously with heparin infusion
Study: 2191783
Drug: Heparin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin without warfarin therapy
Study: 419977
Drug: Pilocarpine eyedrops
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine eyedrops (2% solution four times daily)
Study: 25389283
Drug: ZRS ≥2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZRS ≥2 and NT-proBNP ≥200 pg/mL
Study: 22996693
Drug: CXCR1/2 allosteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCR1/2 allosteric inhibitor reparixin
Study: 12017346
Drug: Eletriptan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan (10 to 120 mg)
Study: 12017346
Drug: Eletriptan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan (30 to 90 mg)
Study: 1751651
Drug: Chlorazepam as
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorazepam as oral premedication (n = 25)
Study: 30195882
Drug: Garlic supplement
Normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplement (1000 mg, twice daily for 12 weeks)
Study: 22169398
Drug: Recommended fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended fluid intake (mean amount 2427 ml)
Study: 22169398
Drug: Low fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluid intake (mean amount 1625 ml)
Study: 19765674
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day for 4 weeks, then 40 mg/day for 4 weeks)
Study: 12060531
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of leflunomide (20 mg, 40 mg, 60 mg)
Study: 12060531
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral administration of leflunomide (20 mg/d for 30 days)
Study: 8578014
Drug: Aerosol inhalation
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol inhalation of fenoterol
Study: 8578014
Drug: Intravenous route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous route of fenoterol
Study: 8578014
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhalers (MDI) inhalation of fenoterol
Study: 8578014
Drug: Aerosol inhalation
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol inhalation of 200 micrograms of fenoterol
Study: 4054195
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg once-daily
Study: 4054195
Drug: pindolol 20
Normalized name: pindolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol 20 mg slow release (SR) once-daily
Study: 27117853
Drug: Resistant Glucan
Normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant Glucan Mixture (RGM) 13.2 g/d
Study: 27117853
Drug: Resistant Glucan
Normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant Glucan Mixture (RGM) 6.6 g/d
Study: 27117853
Drug: Resistant Glucan
Normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant Glucan Mixture (RGM) 3.3 g/d
Study: 26307122
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy for proximal plantar fasciitis (type of foot support not specified)
Study: 23279560
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) with escalating vouchers for on-time alcohol-negative tests (n-BrAC; <0.02 g/dl)
Study: 21700935
Drug: Group 3b
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3b (eGFR 30.0 to 44.9 mL/min/1.73 m²)
Study: 21700935
Drug: Group 3a
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3a (eGFR 45.0 to 59.9 mL/min/1.73 m²)
Study: 21700935
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (eGFR 60.0 to 89.9 mL/min/1.73 m²)
Study: 21700935
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (eGFR ≥ 90.0 mL/min/1.73 m²)
Study: 19086960
Drug: mesalamine foam
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mesalamine foam 1 g/80 mL/day
Study: 19086960
Drug: mesalamine liquid
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mesalamine liquid enema 1 g/100 mL/day
Study: 14996064
Drug: Chloroatranol 5
Normalized name: chlorobutanol 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroatranol 5 p.p.m. solution applied for 14 days
Study: 14996064
Drug: Chloroatranol 25
Normalized name: Chlorobutanol
DrugBank: Chlorobutanol (DB11386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroatranol 25 p.p.m. solution applied for additional 14 days if no reaction to 5 p.p.m.
Study: 14996064
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing with chloroatranol